PET/CT scan for medullary thyroid carcinoma
Part of Cancer clinical trials.
This study tests a new imaging agent (68Ga-DOTA-CCK-FS) that helps doctors see medullary thyroid carcinoma (MTC) and other tumors with CCK-2 receptors using a PET/CT scan. It may help find or monitor these tumors more clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed or suspected diagnosis of medullary thyroid carcinoma (MTC) or another tumor that has CCK-2 receptors.
- You are expected to live at least 12 weeks or more.
- You do not have severe liver or kidney problems.
- You are not pregnant, nursing, or planning to become pregnant during the study.
- You are able to lie still for a PET/CT scan and do not have severe claustrophobia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special imaging agent (FAPI) can help surgeons remove medullary thyroid cancer more precisely during your first surgery. It is for people who have not yet been treated and are scheduled for surgery within 30 days.
This study looks at how well PET-CT scans can find thyroid or parathyroid problems. The trial uses scans that are already part of your regular care to learn more about these conditions.
This trial uses a special PET scan to help guide surgery for medullary thyroid cancer (MTC). The goal is to see if this scan can make surgery more precise.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This trial tests a new imaging tracer called TATE-RGD to see if it can better spot certain tumors when used with a standard PET/CT scan. If you have cancer, you may be able to help by getting two scans a week apart.
This trial tests a new PET scan tracer to find neuroendocrine tumors in the body. It may help doctors see where the tumors are and plan better treatment.
Hear when a new Medullary Thyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.